How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Consumer Goods and Retail · Forecast 2027–2033
Cosmetics Safety and Efficacy Testing Market
- By Test Type: In vitro Testing, In vivo Testing, Clinical Trials, Patch Testing, Microbiological Testing
- By Tested Product Type: Skincare Products, Haircare Products, Makeup Products, Fragrances, Personal Hygiene Products
- By Testing Methodology: Toxicological Assessment, Dermal Irritation and Sensitization Testing, Phototoxicity Testing, Genotoxicity Testing, Eye Irritation Testing
- By End-User: Cosmetics Manufacturers, Contract Research Organizations (CROs), Academic and Research Institutes, Regulatory Bodies
- By Testing Purpose: Safety Assessment, Efficacy Evaluation, Stability Testing, Shelf-life Determination, Regulatory Compliance Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In vitro Testing leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Cosmetics Safety and Efficacy Testing Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Tested Product Type 5
Testing Methodology 5
End-User 4
Testing Purpose 5
Companies profiled
Eurofins Scientific
Intertek Group plc
SGS SA
Covance Inc. (Labcorp)
Charles River Laboratories International Inc.
Piramal Pharma Solutions
WuXi AppTec
Bureau Veritas S.A.
TÜV SÜD
QIMA
NAMSA
BioReliance (Merck KGaA)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Intertek Group plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →SGS SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Covance Inc. (Labcorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Piramal Pharma Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →WuXi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bureau Veritas S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →TÜV SÜD
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →QIMA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →NAMSA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BioReliance (Merck KGaA)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Evotec SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ICON plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Pharmaron
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,118M by 2033 · 4.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In vitro Testing47.9
- In vivo Testing7.3
- Clinical Trials19.5
- Patch Testing13.6
- Microbiological Testing11.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$512.0M → $718.7M · 4.3%
Europe$356.9M → $435.6M · 2.5%
Asia Pacific$325.8M → $432.9M · 3.6%
Latin America$201.7M → $270.7M · 3.7%
Middle East and Africa$155.2M → $205.6M · 3.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.912026
3.932027
3.952028
3.962029
3.972030
3.992031
3.982032
4.002033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eurofins Scientific17.4
- Intertek Group plc18.1
- SGS SA9.8
- Covance Inc. (Labcorp)10.1
- Charles River Laboratories International Inc.8.9
- Piramal Pharma Solutions7.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type25.3%
Tested Product Type14.7%
Testing Methodology11.2%
End-User26.1%
Testing Purpose22.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe21.1
- Asia Pacific21.0
- Latin America13.1
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eurofins Scientific | 81 | 92 | 90 | 91 | 89 | 98 | 90 |
| Intertek Group plc | 88 | 78 | 91 | 90 | 79 | 68 | 82 |
| SGS SA | 84 | 69 | 82 | 81 | 68 | 66 | 75 |
| Covance Inc. (Labcorp) | 62 | 68 | 63 | 58 | 77 | 57 | 64 |
| Charles River Laboratories International Inc. | 60 | 71 | 65 | 68 | 63 | 66 | 66 |
| Piramal Pharma Solutions | 51 | 70 | 46 | 50 | 59 | 46 | 54 |
| WuXi AppTec | 57 | 51 | 50 | 50 | 65 | 63 | 56 |
| Bureau Veritas S.A. | 53 | 41 | 54 | 38 | 35 | 47 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eurofins Scientific
- Intertek Group plc
- SGS SA
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eurofins Scientific | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Intertek Group plc | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| SGS SA | ◐ | ◐ | ◐ | ◐ | − | − |
| Covance Inc. (Labcorp) | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Charles River Laboratories International Inc. | − | ◐ | ◐ | − | ✓ | − |
| Piramal Pharma Solutions | ◐ | ◐ | − | − | ◐ | − |
| WuXi AppTec | − | − | − | ◐ | ◐ | ◐ |
| Bureau Veritas S.A. | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eurofins Scientific90
2Intertek Group plc82
3SGS SA75
4Charles River Laboratories International Inc.66
5Covance Inc. (Labcorp)64
6WuXi AppTec56
7Piramal Pharma Solutions54
8Bureau Veritas S.A.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Eurofins ScientificIntertek Group plc
Challenger1
Strong scale, closing on the leaders.
SGS SA
Contender2
Focused players with pockets of strength.
Covance Inc. (Labcorp)Charles River Laboratories International Inc.
Niche3
Specialists in a single segment or region.
Piramal Pharma SolutionsWuXi AppTecBureau Veritas S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Cosmetics Safety and Efficacy Testing Market — a $366M beachhead inside a $6.22B market.
Beachhead (SOM)$366Mobtainable near-term
Serviceable (SAM)$2.12Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
In vitro Testing
Best fit — highest urgency & budget in Test Type.
Economic buyer76 fit
In vivo Testing
Strong fit — clear ROI and a fast path to value.
End user64 fit
Clinical Trials
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tested Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Testing Methodology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cosmetics Safety and Efficacy Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won6%
$17.6KCAC
$93KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cosmetics Safety and Efficacy Testing Market is a durable-growth opportunity — $5.32B by 2033, compounding at 7.9%.
TAM · 2025$2.89Btoday
TAM · 2033$5.32Bforecast
CAGR7.9%2027–2033
Cumulative$36.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.32BTotal addressable market
SAM$2.18BServiceable available market
SOM$352MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.32BLarge & growingTAM by 2033 at 7.9% CAGR
$2.18BServiceable nowreachable with today’s model
$352MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.15BBear5.1% CAGR
$5.32BBase7.9% CAGR
$6.80BBull10.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tested Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cosmetics Safety and Efficacy Testing Market — a $1.35B market by 2033. Plan: grow share from 6.6% to 11.9%.
Market size · 2033$1.35Btotal addressable
Market CAGR8.0%2027–2033
Target share11.9%from 6.6% today
Revenue ambition$161Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.6% | 11.9% | Behind |
| Revenue | $91M | $161M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 33.3% | 38.4% | On track |
| Customer retention | 91.9% | 96.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tested Product Type capability
A defensible second engine — invest in Tested Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tested Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $23M capacity & capability investment
- Greenlight bolt-on M&A in Tested Product Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cosmetics Safety and Efficacy Testing Market conversation — a $1.95B market you can size, segment and defend in minutes.
Market size · 2033$1.95Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,793+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Eurofins ScientificIntertek Group plcSGS SACovance Inc. (Labcorp)Charles River Laboratories International Inc.Piramal Pharma SolutionsWuXi AppTecBureau Veritas S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cosmetics Safety and Efficacy Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cosmetics Safety and Efficacy Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Consumer Goods and Retail · scroll →Feeding Pillow Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCosmetics Retailer Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCosmetics Regulatory Consultant Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportFoam Facial Cleanser Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCosmetics Regulatory Compliance Consulting Services Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCosmetics Procurement Platform Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportMen’s Facial Cleaning Instruments Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCosmetics Private Label and Contract Manufacturing Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportSingle Control Switch Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCosmetics Preservative Caprylhydroxamic Acid Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportHeated Soaking Tub Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCosmetic Spray Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.